Ultime notizie per Staar Surgical (NASDAQ:STAA) Azioni

STAAR SURGICAL CO

Staar Surgical

Staar Surgical Co is a manufacturer of lenses. It designs, develops, manufactures, and sells implantable lenses for the eye and delivery systems used to deliver the lenses into the eye. The company also makes lenses that are used in surgery to treat cataracts. The company offers two types of products: Implantable Collamer lenses (ICL) and intraocular lens (IOL). The ICLs are used in refractive surgery and IOLs are used in cataract surgery. The majority of its sales are generated from the ophthalmic surgical product segment.

Staar Surgical Co

Canaccord Genuity analyst Jon Young maintains Staar Surgical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STAA#NASDAQ">STAA</a>) with a Hold and raises the price target from $17 to $20.

News

Price Target

Analyst Ratings

STAA

Canaccord Genuity Maintains Hold on Staar Surgical, Raises Price Target to $20

WIIM

STAA stock has given up its prior loss. STAAR Surgical shares were trading lower after the company reported mixed Q1 financial results.

<h3>Gainers</h3>
<ul>
<li>Alvotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALVO#NASDAQ">ALVO</a>) shares increased by 17.4% to $9.32 during Wednesday's after-market session. The market value of their outstanding shares is at $2.8 billion. As per the press release, Q1 earnings came out today. </li>
<li>Generation Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GBIO#NASDAQ">GBIO</a>) stock increased by 15.38% to $0.45. The company's market cap stands at $30.1 million. As per the press release, Q1 earnings came out today. </li>
<li>Revolution Medicines (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RVMD#NASDAQ">RVMD</a>) stock increased by 12.9% to $42.52. The company's market cap stands at $7.9 billion. The company's, Q1 earnings came out today. </li>
<li>GoodRx Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GDRX#NASDAQ">GDRX</a>) stock increased by 8.97% to $4.13. The market value of their outstanding shares is at $1.4 billion. As per the press release, Q1 earnings came out today. </li>
<li>CARISMA Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CARM#NASDAQ">CARM</a>) shares increased by 8.79% to $0.23. The company's market cap stands at $9.7 million. </li>
<li>Emergent BioSolutions (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EBS#NYSE">EBS</a>) stock increased by 8.43% to $5.14. The company's market cap stands at $279.2 million. The company's, Q1 earnings came out today. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>NuCana (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NCNA#NASDAQ">NCNA</a>) shares decreased by 70.2% to $0.09 during Wednesday's after-market session. </li>
<li>electroCore (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ECOR#NASDAQ">ECOR</a>) stock decreased by 14.08% to $5.85. The market value of their outstanding shares is at $42.0 million. The company's, Q1 earnings came out today. </li>
<li>LogicMark (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LGMK#NASDAQ">LGMK</a>) stock fell 13.98% to $0.01. </li>
<li>Exagen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XGN#NASDAQ">XGN</a>) stock declined by 13.47% to $5.91. The company's market cap stands at $105.7 million. The company's, Q1 earnings came out 2 days ago. </li>
<li>Staar Surgical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STAA#NASDAQ">STAA</a>) stock decreased by 12.04% to $17.1. The company's market cap stands at $846.8 million. As per the news, the Q1 earnings report came out today. </li>
<li>AquaBounty Techs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AQB#NASDAQ">AQB</a>) shares fell 10.18% to $0.66. The company's market cap stands at $2.5 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

ALVO

CARM

ECOR

GBIO

GDRX

LGMK

NCNA

RVMD

12 Health Care Stocks Moving In Wednesday's After-Market Session

STAAR Surgical shares are trading lower after the company reported mixed Q1 financial results.

Staar Surgical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STAA#NASDAQ">STAA</a>) reported quarterly losses of $(0.64) per share which missed the analyst consensus estimate of $(0.59) by 8.47 percent. This is a 814.29 percent decrease over losses of $(0.07) per share from the same period last year. The company reported quarterly sales of $42.59 million which beat the analyst consensus estimate of $40.30 million by 5.69 percent. This is a 44.94 percent decrease over sales of $77.36 million the same period last year.

Earnings

Earnings Beats

Earnings Misses

Staar Surgical Q1 Adj. EPS $(0.64) Misses $(0.59) Estimate, Sales $42.59M Beat $40.30M Estimate

ACAD

ACDC

ACRE

ACVA

ADMA

ADNT

ADTN

AIRG

ALNT

ALTG

ALTO

AMPH

AMPL

AMRK

AMRN

AOSL

APLS

ARIS

ARMN

ASLE

Avadel Pharmaceuticals plc - American Depositary Shares each representing one Ordinary Share

AVDL

AVDX

AXON

AXTA

AZTA

BAND

BBDO

BBGI

BBSI

BGSF

Brighthouse Financial, Inc. - Common Stock

BLBD

BLMN

BLZE

BMBL

BRKR

BROS

BTMD

BXSL

BYND

CAPL

CCSI

CDLX

CENT

CENTA

CENX

CEVA

CIVI

CMTG

CNDT

COHR

Core Scientific, Inc. - Class A Common Stock

CORZ

CPRX

CRNC

CRNT

CSGS

CSTE

CTVA

CVNA

CYRX

Earnings Scheduled For May 7, 2025

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Mizuho analyst Uy Ear initiated coverage on Tectonic Therapeutic, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TECX#NASDAQ">TECX</a>) with an Outperform rating and announced a price target of $51. Tectonic Therapeutic shares closed at $17.02 on Thursday. <a href="https://www.benzinga.com/quote/TECX/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>JP Morgan analyst Richard Choe initiated coverage on Dycom Industries, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DY#NYSE">DY</a>) with an Overweight rating and announced a price target of $200. Dycom Industries shares closed at $154.51 on Thursday. <a href="https://www.benzinga.com/quote/DY/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Barclays analyst Adrienne Yih initiated coverage on Abercrombie &amp; Fitch Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ANF#NYSE">ANF</a>) with an Equal-Weight rating and announced a price target of $71. Abercrombie &amp; Fitch shares closed at $72.98 on Thursday. <a href="https://www.benzinga.com/quote/ANF/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>William Blair analyst Stephen Sheldon initiated coverage on Zillow Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/Z#NASDAQ">Z</a>) with a Market Perform rating. Zillow shares closed at $62.57 on Thursday. <a href="https://www.benzinga.com/quote/Z/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Wells Fargo initiated coverage on STAAR Surgical Company (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STAA#NASDAQ">STAA</a>) with an Equal-Weight rating and announced a price target of $17. Staar Surgical shares closed at $16.89 on Thursday.  <a href="https://www.benzinga.com/quote/STAA/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying DY stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="590" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/21080134/image-35-1024x590.png" alt="" class="wp-image-879530" style="width:590px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/21080134/image-35-1024x590.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/21080134/image-35-300x173.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/21080134/image-35-768x442.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/21080134/image-35.png 1096w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/25/04/44862261/top-3-materials-stocks-that-are-ticking-portfolio-bombs">Top 3 Materials Stocks That Are Ticking Portfolio Bombs</a> </li>
</ul>
Photo via Shutterstock

Initiation

Pre-Market Outlook

Markets

Trading Ideas

TECX

This Dycom Industries Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday

Wells Fargo initiates coverage on Staar Surgical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STAA#NASDAQ">STAA</a>) with a Equal-Weight rating and announces Price Target of $17.

Wells Fargo Initiates Coverage On Staar Surgical with Equal-Weight Rating, Announces Price Target of $17

Staar Surgical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STAA#NASDAQ">STAA</a>) has been analyzed by 5 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $19.6, a high estimate of $28.00, and a low estimate of $16.00. Observing a downward trend, the current average is 35.1% lower than the prior average price target of $30.20. 
<img src="https://www.benzinga.com/files/images/story/2025/1742306455_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
The perception of Staar Surgical by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mason Carrico</td>
<td>Stephens &amp; Co.</td>
<td>Maintains</td>
<td>Equal-Weight</td>
<td>$17.00</td>
<td>$17.00</td>
</tr>
<tr>
<td>Jon Young</td>
<td>Canaccord Genuity</td>
<td>Lowers</td>
<td>Hold</td>
<td>$17.00</td>
<td>$28.00</td>
</tr>
<tr>
<td>Thomas Stephan</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Buy</td>
<td>$20.00</td>
<td>$38.00</td>
</tr>
<tr>
<td>Mason Carrico</td>
<td>Stephens &amp; Co.</td>
<td>Maintains</td>
<td>Equal-Weight</td>
<td>$28.00</td>
<td>$28.00</td>
</tr>
<tr>
<td>Matt O'Brien</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$16.00</td>
<td>$40.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Staar Surgical. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Staar Surgical compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of Staar Surgical's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Staar Surgical's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/STAA/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Staar Surgical analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>Get to Know Staar Surgical Better</h2>
Staar Surgical Co is a manufacturer of lenses. It designs, develops, manufactures, and sells implantable lenses for the eye and delivery systems used to deliver the lenses into the eye. The company also makes lenses that are used in surgery to treat cataracts. The company offers two types of products: Implantable Collamer lenses (ICL) and intraocular lens (IOL). The ICLs are used in refractive surgery and IOLs are used in cataract surgery. The majority of its sales are generated from the ophthalmic surgical product segment.
<h3>Unraveling the Financial Story of Staar Surgical</h3>
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Challenges: Staar Surgical's revenue growth over 3 months faced difficulties. As of 31 December, 2024, the company experienced a decline of approximately -35.82%. This indicates a decrease in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: Staar Surgical's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of -69.92%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Staar Surgical's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -8.29% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Staar Surgical's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of -6.54%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: Staar Surgical's debt-to-equity ratio is below the industry average at 0.1, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>Analyst Ratings: Simplified</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Expectations For Staar Surgical's Future

Stephens &amp; Co. analyst Mason Carrico reiterates Staar Surgical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STAA#NASDAQ">STAA</a>) with a Equal-Weight and maintains $17 price target.

Reiteration

Stephens & Co. Reiterates Equal-Weight on Staar Surgical, Maintains $17 Price Target

<ul>
<li>Warren Foust Named President and Chief Operating Officer</li>
<li>Magda Michna, PhD Appointed Chief Development Officer</li>
<li>Deborah Andrews, STAAR's Chief Financial Officer from 2017- 2020, to serve as Interim Chief Financial Officer</li>
<li>Patrick F. Williams Steps Down as Chief Financial Officer</li>
<li>Keith Holliday Retires as Chief Technology Officer</li>
</ul>

Reported Earlier, Staar Surgical Realigns Executive Team; Warren Foust Named President & COO, Deborah Andrews Appointed Interim CFO

U.S. stocks were lower, with the Nasdaq Composite falling around 650 points on Monday.
Shares of Redfin Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RDFN#NASDAQ">RDFN</a>) rose sharply during Monday's session after Rocket Companies announced it will acquire the company in an all-stock transaction valued at $12.50 per share.
Under the terms of the agreement, Redfin shareholders will receive 0.7926 shares of Rocket Class A common stock for each Redfin share—a 63% premium over Redfin&#8217;s 30-day volume-weighted average price. Rocket shareholders will own approximately 95% of the combined company upon completion, with Redfin shareholders holding the remaining 5%.
Redfin shares jumped 70% to $9.89 on Monday.
Here are some other big stocks recording gains in today's session.
<ul>
<li>Mineralys Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MLYS#NASDAQ">MLYS</a>) gained 53% to $16.09 after the company reported topline data from its pivotal LAUNCH-HTN Phase 3 and ADVANCE-HTN Phase 2 trials of Lorundrostat for hypertension. Both trials met the primary endpoint.</li>
<li>Trevi Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRVI#NASDAQ">TRVI</a>) surged 41.8% to $6.10 after the company reported topline results from its Phase 2a RIVER trial of Haduvio for RCC, which met the primary endpoint.</li>
<li>Protagonist Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTGX#NASDAQ">PTGX</a>) rose 41% to $54.08 after the company announced topline results from its Phase 2b ANTHEM-UC study of icotrokinra in ulcerative colitis. The study met its primary endpoint in all dose groups evaluated.</li>
<li>LZ Technology Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LZMH#NASDAQ">LZMH</a>) gained 17.7% to $14.18.</li>
<li>Veren Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VRN#NYSE">VRN</a>) gained 15.6% to $5.68 after the company announced a $15 billion strategic merger with Whitecap to form a leading oil producer.</li>
<li>WK Kellogg Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KLG#NYSE">KLG</a>) rose 9.3% to $21.91.</li>
<li>Dave &amp; Buster&#8217;s Entertainment, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLAY#NASDAQ">PLAY</a>) gained 8.9% to $21.02.</li>
<li>e.l.f. Beauty, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ELF#NYSE">ELF</a>) rose 8.4% to $76.61.</li>
<li>Kratos Defense &amp; Security Solutions, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KTOS#NASDAQ">KTOS</a>) gained 8.2% to $29.53. Kratos said its OpenEdge 2500 achieved DIFI compliance.</li>
<li>STAAR Surgical Company (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STAA#NASDAQ">STAA</a>) rose 7.2% to $19.66.</li>
<li>Harley-Davidson, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HOG#NYSE">HOG</a>) gained 6.9% to $27.90.</li>
<li>Archer-Daniels-Midland Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ADM#NYSE">ADM</a>) climbed 5.5% to $52.16.</li>
<li>Insperity, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NSP#NYSE">NSP</a>) shares rose 5.4% to $95.24.</li>
<li>Tractor Supply Company (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSCO#NASDAQ">TSCO</a>) gained 4.6% to $59.54.</li>
<li>The Campbell&#8217;s Company (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CPB#NASDAQ">CPB</a>) rose 4.4% to $43.65.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/25/03/44187903/top-2-consumer-stocks-that-could-blast-off-this-quarter">Top 2 Consumer Stocks That Could Blast Off This Quarter</a></li>
</ul>

Intraday Update

KTOS

LZMH

MLYS

PLAY

PTGX

RDFN

TRVI

TSCO

Redfin, Mineralys Therapeutics, Trevi Therapeutics And Other Big Stocks Moving Higher On Monday

Needham analyst David Saxon reiterates Staar Surgical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STAA#NASDAQ">STAA</a>) from Hold to Hold.

Needham Reiterates Hold on Staar Surgicalto Hold

Management

STAAR Surgical Appoints Stephen Farrell As CEO, Elizabeth Yeu As Board Chair

Canaccord Genuity analyst Jon Young maintains Staar Surgical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STAA#NASDAQ">STAA</a>) with a Hold and lowers the price target from $28 to $17.

Canaccord Genuity Maintains Hold on Staar Surgical, Lowers Price Target to $17

<h3>Gainers</h3>
<ul>
<li>Xilio Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XLO#NASDAQ">XLO</a>) shares increased by 107.0% to $1.36 during Wednesday's pre-market session. The market value of their outstanding shares is at $62.1 million. </li>
<li>Tivic Health Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TIVC#NASDAQ">TIVC</a>) shares rose 76.29% to $0.41. The company's market cap stands at $3.4 million. </li>
<li>NKGen Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NKGN#NASDAQ">NKGN</a>) shares rose 34.25% to $0.51. The market value of their outstanding shares is at $18.0 million. </li>
<li>Windtree Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WINT#NASDAQ">WINT</a>) shares increased by 33.87% to $0.21. The market value of their outstanding shares is at $1.9 million. </li>
<li>Firefly Neuroscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AIFF#NASDAQ">AIFF</a>) shares rose 28.69% to $10.81. The market value of their outstanding shares is at $86.4 million. </li>
<li>Kindly MD (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KDLY#NASDAQ">KDLY</a>) shares increased by 24.5% to $1.77. The company's market cap stands at $10.5 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Staar Surgical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STAA#NASDAQ">STAA</a>) shares declined by 33.8% to $14.49 during Wednesday's pre-market session. The market value of their outstanding shares is at $714.0 million. As per the news, the Q4 earnings report came out yesterday. </li>
<li>Kala Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KALA#NASDAQ">KALA</a>) shares fell 21.88% to $8.5. The market value of their outstanding shares is at $51.7 million. </li>
<li>Lixte Biotechnology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LIXT#NASDAQ">LIXT</a>) stock declined by 14.51% to $1.65. The company's market cap stands at $3.7 million. </li>
<li>IN8bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INAB#NASDAQ">INAB</a>) stock declined by 11.48% to $0.27. The company's market cap stands at $19.6 million. </li>
<li>Universe Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UPC#NASDAQ">UPC</a>) shares fell 11.3% to $0.17. The market value of their outstanding shares is at $1.4 million. </li>
<li>Ocean Biomedical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OCEA#NASDAQ">OCEA</a>) shares declined by 10.01% to $0.18. The company's market cap stands at $6.2 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AIFF

INAB

KALA

KDLY

LIXT

NKGN

OCEA

TIVC

WINT

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

In the latest quarter, 4 analysts provided ratings for Staar Surgical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STAA#NASDAQ">STAA</a>), showcasing a mix of bullish and bearish perspectives.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $23.0, a high estimate of $28.00, and a low estimate of $16.00. Observing a downward trend, the current average is 32.85% lower than the prior average price target of $34.25. 
<img src="https://www.benzinga.com/files/images/story/2025/1739390453_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Staar Surgical. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Thomas Stephan</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Buy</td>
<td>$20.00</td>
<td>$38.00</td>
</tr>
<tr>
<td>Mason Carrico</td>
<td>Stephens &amp; Co.</td>
<td>Maintains</td>
<td>Equal-Weight</td>
<td>$28.00</td>
<td>$28.00</td>
</tr>
<tr>
<td>Matt O'Brien</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$16.00</td>
<td>$40.00</td>
</tr>
<tr>
<td>Jon Young</td>
<td>Canaccord Genuity</td>
<td>Lowers</td>
<td>Hold</td>
<td>$28.00</td>
<td>$31.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Staar Surgical. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Staar Surgical compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of Staar Surgical's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Staar Surgical's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/STAA/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Staar Surgical analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>All You Need to Know About Staar Surgical</h2>
Staar Surgical Co is a manufacturer of lenses. It designs, develops, manufactures, and sells implantable lenses for the eye and delivery systems used to deliver the lenses into the eye. The company also makes lenses that are used in surgery to treat cataracts. The company offers two types of products: Implantable Collamer lenses (ICL) and intraocular lens (IOL). The ICLs are used in refractive surgery and IOLs are used in cataract surgery. The majority of sales are generated from the ophthalmic surgical product segment.
<h3>A Deep Dive into Staar Surgical's Financials</h3>
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Staar Surgical's remarkable performance in 3 months is evident. As of 30 September, 2024, the company achieved an impressive revenue growth rate of 10.31%. This signifies a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Staar Surgical's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 11.27%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Staar Surgical's ROE excels beyond industry benchmarks, reaching 2.38%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Staar Surgical's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 1.9%, the company showcases efficient use of assets and strong financial health.
Debt Management: With a below-average debt-to-equity ratio of 0.09, Staar Surgical adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

On Tuesday, Staar Surgical Company (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STAA#NASDAQ">STAA</a>) reported a fourth-quarter 2024 EPS loss of 69 cents, a turnaround from an income of 16 cents, missing the <a href="https://www.benzinga.com/calendars/earnings" target="_blank" rel="noreferrer noopener">consensus loss of 16 cents</a>.
The contact lens maker reported sales of $48.95 million, compared to $76.3 million in the prior year quarter, missing the consensus of $77.3 million.
The decrease was due to a significant decline in China revenue, driven by worsening trends in overall <a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/b43639788/staar-surgical-reports-fourth-quarter-and-fiscal-year-2024-results" rel="noreferrer noopener">refractive procedure volumes</a>.
Implantable Collamer Lens&nbsp;(ICL) sales were $46.9 million for the fourth quarter of 2024 compared to $74.6 million in the prior year quarter.
Also Read: <a target="_blank" href="https://www.benzinga.com/24/12/42274583/morgan-stanley-maintains-positive-medtech-outlook-despite-setbacks-in-2024-upgrades-intuitive-surgical-and-stryker-downgrades-nevro-and-glaukos" rel="noreferrer noopener">Morgan Stanley Maintains Positive MedTech Outlook Despite Setbacks in 2024, Upgrades Intuitive Surgical And Stryker, Downgrades Nevro And Glaukos</a>
Excluding China, ICL sales were $39.5 million, an increase of 17%.
In December 2024, the company shipped $27.5 million of ICLs to China, for which it did not recognize revenue due to extended payment terms with its distributor.
The company determined to keep product in-country before the anticipated demand rebound in the second half of 2025 and mitigate potential impacts from geopolitical and tariff changes.
Based on the extended payment terms, Staar Surgical expects to receive full payment and fully recognize this revenue by the end of the fiscal quarter ending September 26, 2025.
The gross profit margin for the fourth quarter of 2024 was 64.7% compared to 79.6% a year ago.
Guidance: Staar Surgical expects 2025 ICL sales Ex. China of approximately $165 million to $175 million, representing approximately 9% to 15% growth, assuming overall refractive procedure volumes in the Americas will be down 5%-10%; EMEA will be flat; and APAC Ex. China will be flat.
China&#8217;s ICL sales will be less than $5 million for the first half of 2025, as the company works through elevated inventory levels against weak demand for refractive in-market procedures.
The company sees China ICL sales of approximately $75 million-$125 million in the second half of 2025, which is dependent on overall refractive procedure volumes in China, which the company believes could be down 10% at the low end.
The high end of this range contemplates a rebound in overall refractive procedure volumes growing 10%.
In fiscal year 2025, the company says it will manage its working capital and implement appropriate cost-cutting measures in light of the lower revenue forecast.
The company intends to lower production output, decrease capital expenditures, and make targeted reductions to operating expenses, which will impact headcount and discretionary spending.
Based on the company's outlook for fiscal year 2025, Staar Surgical no longer expects to achieve its Vision 2026 Target Sales and Operating Model, initially announced in September 2023.
William Blair downgraded Staar Surgical to <a target="_blank" href="https://www.benzinga.com/quote/STAA/analyst-ratings" rel="noreferrer noopener">a Market Perform rating</a> given the lack of visibility, uncertainty around stimulus to date, and increasing competition in the region amid what appears to be another year of global refractive market contraction in 2025.
Price Action: Staar Surgical stock is down 38.6% at $13.44 during the premarket session on last check Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/25/02/43653433/softbank-q3-earnings-revenue-rises-vision-fund-takes-2-33-billion-hit-as-investments-falter" target="_blank" rel="noreferrer noopener">SoftBank Q3 Earnings: Revenue Rises, Vision Fund Takes $2.33 Billion Hit As Investments Falter</a></li>
</ul>

Analyst Color

Guidance

Downgrades

Health Care

General

Eye Lens Maker Staar Surgical Stock Sinks As Sales Drop To $49 Million, Analyst Downgrades

Stifel analyst Thomas Stephan maintains Staar Surgical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STAA#NASDAQ">STAA</a>) with a Buy and lowers the price target from $38 to $20.

Stifel Maintains Buy on Staar Surgical, Lowers Price Target to $20

Stephens &amp; Co. analyst Mason Carrico reiterates Staar Surgical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STAA#NASDAQ">STAA</a>) with a Equal-Weight and maintains $28 price target.

Stephens & Co. Reiterates Equal-Weight on Staar Surgical, Maintains $28 Price Target

Small Cap

Press Releases

STAA Investors Have Opportunity to Join STAAR Surgical Company Fraud Investigation with the Schall Law Firm

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of STAAR Surgical Company. - STAA

STAAR Surgical Announces Leadership Transition

STAAR Surgical Announces Realignment of Leadership Structure

STAAR Surgical to Host First Quarter 2025 Earnings Conference Call and Webcast on May 7, 2025

Comments

Staar Surgical

Notizie

Ultime notizie per Staar Surgical (NASDAQ:STAA) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO